. Author manuscript; available in PMC: 2010 Aug 15.

Published in final edited form as: J Immunol. 2009 Jul 20;183(4):2312–2320. doi: 10.4049/jimmunol.0900185

Table I. GFP expression by splenic leukocytes at baseline and after in vivo stimulation with LPS^a.

Cell Type	Vert-X (naive)	Vert-X LPS
Total leukocytes	1.3 ± 0.1	10.4 ± 0.6^***
CD19⁺B220⁺	1.1 ± 0.1	14.1 ± 0.8^***
CD19⁺B220^low/-	35.4 ± 3.4	56.7 ± 5.0^*
CD19⁺CD138⁺	7.1 ± 1.2	64.6 ± 3.5^***
TCR⁺CD4⁺CD25⁺	4.7 ± 0.2	5.6 ± 0.3^*
TCR⁺CD4⁺CD25^-	1.2 ± 0.1	1.9 ± 0.2^*
TCR⁺CD8⁺	0.4 ± 0.06	3.5 ± 0.3^***
CD11b⁺	0.5 ± 0.1	7.5 ± 1.2^***
CD11b⁺GR1⁺	0.6 ± 0.2	1.2 ± 0.4 (NS)
CD11c^high	0.7 ± 0.2	2.2 ± 0.4^**
NK1.1⁺TCR⁺	0.4 ± 0.1	1.2 ± 0.5 (NS)
NK1.1⁺TCR^-	0.7 ± 0.1	3.9 ± 0.2^***

Age- and sex-matched wildtype and Vert-X mice were challenged intravenously with TLR4-specific LPS (E. coli K12, 20 μg) or left unchallenged. 48 h after stimulation, splenic leukocytes were analyzed by flow cytometry. Data represent the mean percentage (± SE) of each cell type that were GFP⁺ (8 mice/group).

P < 0.05

^**

P < 0.001

^***

P < 0.0001 (Student’s t-test)

NS, not significant. Results similar to those in naive mice were seen after in vivo challenge with PBS (data not shown).

Table I. GFP expression by splenic leukocytes at baseline and after in vivo stimulation with LPSa.

Table I. GFP expression by splenic leukocytes at baseline and after in vivo stimulation with LPS^a.